Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe

Contributed by: Business Wire

Logo

Tags

Oncology

Health

General Health

Research

Science

Pharmaceutical

Biotechnology

Orion

More Like This

PR Newswire associated0

SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev®in Europe

PR Newswire associated0

Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)

PR Newswire associated0

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

Navamedic and Orion Corporation sign License & Supply Agreement for Flexilev® in Europe

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars